Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).
S. Verstovsek
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Geron; Incyte; Lilly; Roche; S*Bio
R. A. Mesa
Research Funding - Celgene; Incyte; S*Bio
J. R. Gotlib
Research Funding - Incyte
R. S. Levy
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
V. Gupta
No relevant relationships to disclose
J. F. DiPersio
Research Funding - Genzyme
J. Catalano
No relevant relationships to disclose
M. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme
C. B. Miller
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Incyte
R. T. Silver
Stock Ownership - Incyte
Research Funding - Incyte
M. Talpaz
Research Funding - Incyte
E. F. Winton
No relevant relationships to disclose
J. H. Harvey
No relevant relationships to disclose
K. Vaddi
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
S. K. Erickson-Viitanen
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
I. Koumenis
Employment or Leadership Position - Incyte
W. Sun
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
V. Sandor
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
H. Kantarjian
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer